« Previous Next » Seminars in Oncology
Volume 37, Issue 1 , Pages 53-59 , February 2010

The Use of Central Laboratories and Remote Electronic Data Capture to Risk-Adjust Therapy for Pediatric Acute Lymphoblastic Leukemia and Neuroblastoma

Meenakshi Devidas
- Children's Oncology Group Statistics and Data Center, College of Medicine, University of Florida, Gainesville, FL
- Department of Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville, FL
- Address correspondence to Meenakshi Devidas, PhD, Department of Epidemiology and Health Policy Research, 104 N Main St, Suite 600, Gainesville, FL 32601
Wendy B. London
- Children's Oncology Group Statistics and Data Center, College of Medicine, University of Florida, Gainesville, FL
- Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, MA
James R. Anderson
- Children's Oncology Group Statistics and Data Center, College of Medicine, University of Florida, Gainesville, FL
- University of Nebraska Medical Center, College of Public Health, Omaha, NE

References

Schultz KR, Pullen J, Sather H, et al. Biology-driven classification of childhood acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109:926–935
- MEDLINE
- CrossRef
Strother D, London WB, Yap J, et al. Surgery and restricted use of chemotherapy as treatment of low-risk neuroblastoma: preliminary results of Children's Oncology Group protocol 9641. Proceedings of the 38th Congress of the International Society of Paediatric Oncology.
Baker DL, Schmidt M, Cohn S, et al. A phase III trial of biologically-based therapy reduction for intermediate risk neuroblastoma [abstract 9504]. 2007 American Society of Clinical Oncology Annual Meeting Proceedings. Part I. 25:18S.
Kreissman SG, Villablanca JG, Diller L, et al. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): a Children's Oncology Group (A3973) study [abstract 9505]. 2007 American Society of Clinical Oncology Annual Meeting Proceedings. Part I. 25:18S.